ASSEMBLY BIOSCIENCES, INC. (ASMB)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-31

Key Insights

The CEO and President, Jason A. Okazaki, acquired 94,250 shares of common stock in the form of restricted stock units (RSUs) which vest over 4 years, indicating his confidence in the company's long-term prospects.
The RSUs granted represent 65% of Okazaki's annual equity grant, with the remaining 35% contingent on stockholder approval of an amendment to increase the shares authorized under the company's equity incentive plan.
Okazaki now beneficially owns 111,916 shares of the company's common stock, further aligning his interests with those of other shareholders.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, William E. Delaney IV, was granted 26,000 restricted stock units (RSUs) as part of his compensation as the Chief Scientific Officer of Assembly Biosciences, Inc. (ASMB).
The RSUs vest over four years in equal installments, indicating a long-term alignment between the reporting person and the company's performance.
A portion of the RSUs (35%) is contingent on stockholder approval of an amendment to the company's stock incentive plan, which could impact the total number of shares available for issuance.

Insider Trading Filed: 2026-03-31

Key Insights

Anuj Gaggar, the Chief Medical Officer, acquired 26,000 shares of ASMB common stock through a restricted stock unit (RSU) grant, indicating his positive outlook on the company's future.
The RSUs vest over a 4-year period, suggesting a long-term commitment from the executive to ASMB.
35% of the RSU grant is contingent on stockholder approval to increase the shares authorized under the company's equity incentive plan, aligning the executive's interests with those of shareholders.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Nicole S. White, acquired 26,000 shares of common stock in the form of restricted stock units (RSUs) on March 29, 2026. This indicates the company is granting equity compensation to retain its Chief Manufacturing Officer.
On March 30, 2026, the reporting person sold 197 shares of common stock to cover tax withholding obligations related to the vesting and settlement of the RSUs. This suggests the reporting person is not selling shares for personal reasons.
The reporting person currently holds 37,477 shares of common stock, indicating they maintain a substantial ownership stake in the company.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Jeanette M. Bjorkquist, received a grant of 6,500 restricted stock units (RSUs) that vest over 4 years, representing 65% of their annual equity award.
The reporting person sold 312 and 16 shares of common stock on March 30, 2026 to cover tax withholding obligations related to the vesting of RSUs, a mandatory 'sell-to-cover' transaction.
The reporting person's beneficial ownership of the company's common stock decreased from 11,417 shares to 11,089 shares as a result of the sell-to-cover transactions.

Current Report Filed: 2026-03-30

Key Insights

Assembly Biosciences has implemented a new 2026 Corporate Bonus Plan to motivate, retain and reward employees based on corporate and individual performance objectives.
The Compensation Committee has approved an increase in the bonus target for the CEO from 60% to 65% of his base salary, effective for fiscal year 2026.
The new bonus plan provides a framework for cash bonus awards that can range from 0 to 1.5 times a participant's bonus target, to be paid in the first quarter following the completion of the performance period.

Current Report Filed: 2026-03-19

Key Insights

Assembly Biosciences reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's recent performance and operations.
The company's press release indicates continued progress in its pipeline of drug candidates, though specific details on clinical development and regulatory milestones were not provided.
Investors will be looking for more comprehensive updates on the company's key programs, as well as any changes to financial guidance or strategic plans, in the company's upcoming earnings call and regulatory filings.

Annual Report Filed: 2026-03-19

Key Insights

The company has a collaboration agreement with Gilead Sciences, which provides a potential revenue stream and strategic partnership.
The company has conducted several private placements and at-the-market offerings to raise capital, indicating ongoing funding needs.
The company has a portfolio of clinical-stage drug candidates, including for the treatment of hepatitis B, which represents a potentially large market opportunity.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.